Pfizer Inc. said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc. in a $2.26 billion deal to strengthen its arsenal of blood cancer therapies.
Pfizer, which acquired a $25 million stake in Trillium last year, will buy the remaining outstanding shares for $18.50 apiece, representing a 203.8 per cent premium on the stock’s last closing price.
Pfizer expects to benefit from Canada-based Trillium’s blood-cancer therapies that target a “don’t eat me” signal used by cancer cells to evade the immune system.
Forty Seven Inc., which is also developing drugs that target the same antibodies, was bought by Gilead Sciences Inc for $4.9 billion last year.
More than 1 million people worldwide were diagnosed with blood cancer in 2020, representing almost 6 per cent of all cancer diagnoses. The same year, more than 700,000 people worldwide died from a form of blood cancer.
Trillium’s U.S.-listed shares were trading at $17.73 before the bell on Monday, having fallen 59 per cent in 2021 as of their last close. Pfizer bought nearly 2.3 million Trillium shares at $10.88 each in September.
Pfizer’s financial adviser for the transaction is BofA Securities Inc, and Centerview Partners LLC is Trillium’s.
More Stories
Feds give financial boost to biofuel sector amid growing U.S. competition | CBC News
Here’s what you need to know about ‘halal mortgages,’ rates
What is a ‘halal mortgage’? Does it make housing more accessible?